Monday, April 19, 2010
Myriad raises price of BRCA testing, again.
On April 1, 2010 - three days after a court ruling that invalidated Myriad's patents on the BRCA1 and BRCA2 genes (associated with hereditary breast and ovarian cancer) the company increased their prices for genetic testing. Old cost =$3,770. New cost = $4,040 for full sequencing plus rearrangement testing.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.